Regenerative Medicines: Bone and Joint Applications

The global regenerative medicine for bone and joint applications market should reach $16.4 billion by 2027 from $9.4 billion in 2022 at a compound annual growth rate (CAGR) of 11.6% for the forecast period of 2022 to 2027.

Report Includes

• 51 tables
• An overview of the global market for regenerative medicines for bone and joint applications
• Estimation of the market size and analyses of global market trends, with data from 2020 to 2021, estimates for 2022, with projections of compound annual growth rates (CAGRs) through 2027
• Characterization and quantification of market potential for regenerative medicines by technology, application, and region
• Coverage and discussion on regulatory delays due to COVID-19, clinical trials and product launches of the industry
• Description of principle approaches to regenerative medicine and discussion on importance of scaffolding in tissue engineering
• Information on major drivers and regional dynamics of the market and current trends within the industry
• Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships and other key market strategies
• Company profiles of major players, including Anika Therapeutics, Conmed Corp., Johnson & Johnson and Stryker Corp.

The U.S. market for regenerative medicine products used in bone and joint applications is expected to grow at a compound annual growth rate (CAGR) of 6.8% from $2.9 billion in 2015 to nearly $4.1 billion in 2020.

Report Includes

• An overview of the market for regenerative medicines in bone and joint applications, whose key objectives are the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process.
• Analyses of market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.
• Coverage of other regenerative applications, such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care, as well as stem cell research.
• Identification of market drivers, including an increase in diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone- and cartilage-growth-stimulating agents in a regenerative appliance.
• Descriptions of products, such as bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.

The U.S. market for regenerative medicine products used in bone and joint applications was estimated to total $2.72 billion in 2012 and is projected to increase to $2.73 billion in 2013. The market should total nearly $3.9 billion by 2018 and have a five-year compound annual growth rate (CAGR) of 7.3%.

Report Includes

• An overview of the market for regenerative medicines in bone and joint applications, whose key objectives are the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process.
• Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Coverage of other regenerative applications, such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care, as well as stem cell research.
• Identification of market drivers, including an increase in diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone- and cartilage-growth-stimulating agents in a regenerative appliance.
• Descriptions of products, such as bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.

• Overall sales in the regenerative medicine productsmarket were worth $1.1 billion in 2007, and remained flat into 2009. By 2014, sales are projected to increase to nearly $1.8 billion, for a 5-year compound annual growth rate (CAGR) of 8.6%.
• The largest segment in the market, bone replacement/grafting, was valued at $714  million in 2007. This also has increased only slightly into 2009 but is projected to reach $979  million in 2014, for a 5-year CAGR of 6.3%.
• Sales in the bone growth stimulators product segment were worth $321  million in 2007, and were to increase slightly into 2009.  By 2014, however, they are projected to increase to $578  million, for a 5-year CAGR of 11.9%.

• The total U.S. market for bone and joint applications of regenerative medicine is projected to rise at an average annual growth rate of 8.5% to reach $1.4 billion in 2007.
• Regenerative medicine refers to technologies that repair or replace diseased or defective tissues or organs. The main types of regenerative medicine utilize products naturally occurring in the body, such as genes and proteins (antibodies, growth factors, hormones); cells and tissues; embryonic stem cells, and biomaterials. At present, most regenerative medicines on the market fall into the first category and include protein-based drugs and therapies containing human cells. However, there are a few products based on tissue engineering. This technology, which promises to be the most exciting and fastest growing sector of regenerative medicine in the near future, is the primary focus of this report. Tissue engineering technologies discussed include matrices and scaffolds, in vitro and in vivo technologies, and novel materials, which include those utilizing nanotechnology (atomic-scale engineering) of inorganic substances that meld with human tissues.